NCT04497766 is a Phase 4 clinical trial of Nebulized Magnesium sulfate in Asthma in Children, sponsored by Saima Khatoon.

Who is sponsoring NCT04497766?

NCT04497766 is sponsored by Saima Khatoon.

What drugs are being tested in NCT04497766?

Interventions in NCT04497766: Nebulized Magnesium sulfate, Intravenous magnesium sulphate.

What condition does NCT04497766 study?

NCT04497766 studies Asthma in Children.

Is NCT04497766 still recruiting?

NCT04497766 is currently completed. Last updated 23 February 2021.

Last reviewed 2021-02-23 · How we verify

NCT04497766

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparasion of Efficacy of Nebulized With Intravenous Magnesium Sulphate in Children With Asthma

Completed Phase 4 Last updated 23 February 2021

What this trial tests

Phase 4 trial testing Nebulized Magnesium sulfate in Asthma in Children in 148 participants. Completed in 30 September 2020.

Timeline

1 October 2019

Primary endpoint
30 September 2020

30 September 2020

Quick facts

Lead sponsor	Saima Khatoon
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	treatment
Enrollment	148
Start date	1 October 2019
Primary completion	30 September 2020
Estimated completion	30 September 2020
Sites	1 location across Pakistan

Drugs / interventions tested

Nebulized Magnesium sulfate — full drug profile →
Intravenous magnesium sulphate — full drug profile →

Conditions studied

Asthma in Children — all drugs for Asthma in Children →

Sponsor

Saima Khatoon — full company profile →

Who can join

Adults 2 to 12, any sex, with Asthma in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of study is to assess the effectiveness of nebulized magnesium sulphate in children presenting with acute asthma.Study perfoma consists of demographic variables,exclusion criteria and pediatric asthma score that includes respiratory rate,SPO2 at room air(requirement of oxygen),auscultatory findings in chest,dysnea and retractions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma in Children

Currently open trials in the same condition.

NCT06372249 — A Clinical Trial of Soluble Fiber for Asthma · Phase 2 · recruiting
NCT07412769 — ASMact: Study on Management of Bronchial Asthma · recruiting
NCT07138027 — SMART Implementation-Effectiveness Trial 2 · NA · recruiting
NCT07137923 — SMART Implementation-Effectiveness Trial 1 · NA · recruiting
NCT06851715 — Improving Quality of Life for Teenagers With Asthma · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04497766 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Saima Khatoon
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04497766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing